HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

VCYT

Veracyte, Inc. (Russell 2000)

Healthcare — Diagnostics & Research

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Buy 1.7 / 5 11 analysts
$55.65
+$0.04 (+0.07%)
Target: $56.55 (1.6%)
Sign in to add VCYT to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$4.44B
P/E Ratio (TTM)51.53
Forward P/E29.49
EPS (TTM)$1.08
Dividend Yield-
Profit Margin16.25%
Revenue Growth21.50%
ROE6.93%
Debt/Equity2.93
Recommendation Buy 1.7
Analyst Target$56.55
Analysts11
Indexes Russell 2000

Technical Indicators

RSI (14)48.7
Beta1.93
SMA 20$57.74
SMA 40$54.64
52-Week High$60.91
52-Week Low$22.92
50-Day Avg$52.18
200-Day Avg$41.50
Avg Volume$1.24M
Volume740.2K

Performance Analysis

BULLISH

VCYT shows predominantly bullish signals based on its fundamentals and technicals.

+ Showing strength at 86% of its 52-week range.
~ RSI at 48.7 is in neutral territory.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
- P/E of 51.5 is elevated — the market expects high growth or it may be overvalued.
+ Strong revenue growth of 21.5% year-over-year.
+ Wall Street consensus is "Buy" from 11 analysts.
+ Average analyst target of $56.55 implies 1.6% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 28, 2026 21:01 UTC

Back to Screener Export Report